Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation

Show full item record



Permalink

http://hdl.handle.net/10138/317810

Citation

Martinez-Corral , I , Zhang , Y , Petkova , M , Ortsater , H , Sjoberg , S , Castillo , S D , Brouillard , P , Libbrecht , L , Saur , D , Graupera , M , Alitalo , K , Boon , L , Vikkula , M & Mäkinen , T 2020 , ' Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation ' , Nature Communications , vol. 11 , no. 1 . https://doi.org/10.1038/s41467-020-16496-y

Title: Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation
Author: Martinez-Corral, Ines; Zhang, Yan; Petkova, Milena; Ortsater, Henrik; Sjoberg, Sofie; Castillo, Sandra D.; Brouillard, Pascal; Libbrecht, Louis; Saur, Dieter; Graupera, Mariona; Alitalo, Kari; Boon, Laurence; Vikkula, Miikka; Mäkinen, Taija
Contributor: University of Helsinki, HUSLAB
Date: 2020-06-08
Language: eng
Number of pages: 14
Belongs to series: Nature Communications
ISSN: 2041-1723
URI: http://hdl.handle.net/10138/317810
Abstract: Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms underlying LM pathology are poorly understood. Here we show that the somatic PIK3CA(H1047R) mutation, resulting in constitutive activation of the p110 alpha PI3K, underlies both macrocystic and microcystic LMs in human. Using a mouse model of PIK3CA(H1047R)-driven LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell (LEC)-autonomous defects, with the developmental timing of p110 alpha activation determining the LM subtype. In the postnatal vasculature, PIK3CA(H1047R) promotes LEC migration and lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways. Lymphatic malformation (LM) is a debilitating often incurable vascular disease. Using a mouse model of LM driven by a disease-causative PIK3CA mutation, the authors show that vascular growth is dependent on the upstream lymphangiogenic VEGF-C signalling, permitting effective therapeutic intervention.
Subject: CEREBRAL CAVERNOUS MALFORMATIONS
PHOSPHOINOSITIDE 3-KINASE P110-ALPHA
GROWTH-FACTOR RECEPTOR-3
ENDOTHELIAL-CELLS
SOMATIC MUTATIONS
2-HIT MECHANISM
LYMPHANGIOGENESIS
HETEROGENEITY
ANGIOGENESIS
PI3K
3111 Biomedicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41467_020_16496_y_1.pdf 6.437Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record